A Review of First-Line Treatment for Small-cell Lung Cancer

@article{Murray2006ARO,
  title={A Review of First-Line Treatment for Small-cell Lung Cancer},
  author={Nevin Murray and Andrew T. Turrisi},
  journal={Journal of Thoracic Oncology},
  year={2006},
  volume={1},
  pages={270-278}
}
Although small-cell lung cancer (SCLC) makes up a smaller proportion of all lung cancers than it did 25 years ago, it remains a common cause of cancer mortality that requires more clinical and basic research than is currently underway. Trials of newer chemotherapy variations have failed to produce a regimen that is clearly superior to the two-drug combination of etoposide and cisplatin, which remains the standard of care for both limited and extensive stage SCLC. Paradoxically, advances in this… Expand
View on Wolters Kluwer
jto.org
108 Citations
Highly Influential Citations
1
Background Citations
27
Methods Citations
3
Results Citations
2

108 Citations

Citation Type

Citation Type

Small cell lung cancer.
TLDR
In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare, and smoking cessation should be strongly promoted. Expand
Small Cell Lung CancerPractice Guidelines in Oncology
TLDR
In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare, and smoking cessation should be strongly promoted. Expand
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
TLDR
Clinical trials of both monotherapy and combination therapy with amRubicin conducted in Japan, the USA, and the European Union suggest that the clinical outcome of amrubicin therapy may be associated with genetic variations in patients. Expand
Therapy of small cell lung cancer with emphasis on oral topotecan.
TLDR
Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy, and is considered as the standard second-line chemotherapy in patients with small cell lung cancer. Expand
Novel systemic therapies for small cell lung cancer.
TLDR
Novel therapeutic approaches based on advances in understanding of the biology of SCLC have the potential to radically change the outlook for patients with this disease. Expand
Update on targeted therapies for small cell carcinoma of the lung
TLDR
Though the clinical data thus far is discouraging, drugs are still undergoing evaluation and more targets continue to be identified and there is considerable scope for further research and in particular combining newer therapies with existing treatment modalities to improve outcomes. Expand
[Analysis of Efficacy of Surgical Treatment for IIIa Small Cell Lung Cancer].
TLDR
In performing further evaluation of the status and value of surgical treatment in the comprehensive treatment of SCLC, several patients benefitted from IIIa SclC surgery with comprehensive treatment. Expand
Update on small cell lung cancer management
Educational aims To describe the relevance of staging, including TNM staging To show the clinical relevance of paraneoplastic syndromes as a presentation of small cell lung cancer To understand the… Expand
Recent Pharmacological Advances: Focus on Small-cell Lung Cancer
TLDR
The mechanisms of action of amrubicin as well as clinical studies which demonstrate the potential of this drug in future SCLC treatment are described and hypothetical considerations for the use of other drugs such as lenalidomide, an immunomodulatory drug acting on multiple signalling pathways, or histone deacetylase inhibitors, in combination with amRubicin in SCLCs are put forward. Expand
The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
TLDR
Continuation with carboplatin/paclitaxel or carboplarin/etoposide as second-line chemotherapy has no significant survival impact, and it did not improve response rates. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Influence of age on the treatment of limited-stage small-cell lung cancer.
PURPOSE To evaluate the prognostic importance of age on response rate and survival in patients with limited-stage small-cell lung cancer (SCLC), and to determine the effect of age on chemotherapy… Expand
Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
TLDR
These interim results show that this schedule of oral etoposide is inferior to intravenous chemotherapy in the treatment of advanced SCLC and should not be used as first-line treatment of this disease. Expand
Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung.
TLDR
The addition of radiotherapy of the primary tumor to combination chemotherapy improved both complete-response rates and survival, with increased but acceptable toxicity. Expand
Radiation dose intensification in limited-stage small-cell lung cancer.
TLDR
The history of radiation therapy in the management of small-cell lung cancer is examined, the rationale for the various approaches to radiation dose intensification is reviewed, and the results of important trials investigating the issue of radiation dose are reviewed. Expand
Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy.
TLDR
The results indicate that the use of TRT fields that encompass postchemotherapy tumor volumes does not increase the risk of marginal failures or intrathoracic failures outside the TRT field. Expand
Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung.
  • R. Klasa, N. Murray, A. Coldman
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
TLDR
It is concluded that DI-outcome correlations are not consistent for these chemotherapy regimens in SCCL. Expand
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.
  • N. Murray, P. Coy, +7 authors P. Dixon
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
The early administration of TI in the combined modality therapy of limited-stage SCLC is superior to late or consolidative TI. Expand
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
TLDR
Four cycles of PE induction therapy followed by four cycles of topotecan improved progression-free survival but failed to improve overall survival or quality of life in extensive-stage SCLC. Expand
Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.
TLDR
Timing of CI did not significantly influence the incidence of in-field recurrences, CNS recurrence, or overall survival, and there was no difference in the frequency and severity of other toxicities between the 2 groups. Expand
Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial
TLDR
Oral etoposide alone is inferior to standard intravenous multidrug chemotherapy in the palliative treatment of patients with SCLC and poor performance status and should no longer be used in the treatment of such patients. Expand
...
1
2
3
4
5
...